139 related articles for article (PubMed ID: 37003134)
1. SOS1-inspired hydrocarbon-stapled peptide as a pan-Ras inhibitor.
Li A; Li X; Zou J; Zhuo X; Chen S; Chai X; Gai C; Xu W; Zhao Q; Zou Y
Bioorg Chem; 2023 Jun; 135():106500. PubMed ID: 37003134
[TBL] [Abstract][Full Text] [Related]
2. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
3. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.
Leshchiner ES; Parkhitko A; Bird GH; Luccarelli J; Bellairs JA; Escudero S; Opoku-Nsiah K; Godes M; Perrimon N; Walensky LD
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1761-6. PubMed ID: 25624485
[TBL] [Abstract][Full Text] [Related]
4. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.
Thompson SK; Buckl A; Dossetter AG; Griffen E; Gill A
Expert Opin Ther Pat; 2021 Dec; 31(12):1189-1204. PubMed ID: 34253125
[No Abstract] [Full Text] [Related]
5. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
Elife; 2020 Sep; 9():. PubMed ID: 32897190
[TBL] [Abstract][Full Text] [Related]
6. Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling.
Luo G; Wang B; Hou Q; Wu X
J Med Chem; 2023 Apr; 66(7):4324-4341. PubMed ID: 36987571
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization of 14-3-3ζ in complex with the human Son of sevenless homolog 1 (SOS1).
Ballone A; Centorrino F; Wolter M; Ottmann C
J Struct Biol; 2018 Jun; 202(3):210-215. PubMed ID: 29408703
[TBL] [Abstract][Full Text] [Related]
8. Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.
Evelyn CR; Duan X; Biesiada J; Seibel WL; Meller J; Zheng Y
Chem Biol; 2014 Dec; 21(12):1618-28. PubMed ID: 25455859
[TBL] [Abstract][Full Text] [Related]
9. Targeting Son of Sevenless 1: The pacemaker of KRAS.
Kessler D; Gerlach D; Kraut N; McConnell DB
Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
[TBL] [Abstract][Full Text] [Related]
10. Targeting RAS oncogenesis with SOS1 inhibitors.
Hillig RC; Bader B
Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.
Burns MC; Howes JE; Sun Q; Little AJ; Camper DV; Abbott JR; Phan J; Lee T; Waterson AG; Rossanese OW; Fesik SW
Anal Biochem; 2018 May; 548():44-52. PubMed ID: 29444450
[TBL] [Abstract][Full Text] [Related]
12. Small Molecule-Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1.
Howes JE; Akan DT; Burns MC; Rossanese OW; Waterson AG; Fesik SW
Mol Cancer Ther; 2018 May; 17(5):1051-1060. PubMed ID: 29440291
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
[TBL] [Abstract][Full Text] [Related]
14. Induction of the Ras activator Son of Sevenless 1 by environmental pollutants mediates their effects on cellular proliferation.
Pierre S; Bats AS; Chevallier A; Bui LC; Ambolet-Camoit A; Garlatti M; Aggerbeck M; Barouki R; Coumoul X
Biochem Pharmacol; 2011 Jan; 81(2):304-13. PubMed ID: 20950586
[TBL] [Abstract][Full Text] [Related]
15. Identification and Characterization of Oncogenic
Cai D; Choi PS; Gelbard M; Meyerson M
Mol Cancer Res; 2019 Apr; 17(4):1002-1012. PubMed ID: 30635434
[TBL] [Abstract][Full Text] [Related]
16. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
[TBL] [Abstract][Full Text] [Related]
17. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S
Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
19. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.
Begovich K; Schoolmeesters A; Rajapakse N; Martinez-Terroba E; Kumar M; Shakya A; Lai C; Greene S; Whitefield B; Okano A; Mali V; Huang S; Chourasia AH; Fung L
Mol Cancer Ther; 2024 Apr; 23(4):407-420. PubMed ID: 38224565
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling.
Abbott JR; Hodges TR; Daniels RN; Patel PA; Kennedy JP; Howes JE; Akan DT; Burns MC; Sai J; Sobolik T; Beesetty Y; Lee T; Rossanese OW; Phan J; Waterson AG; Fesik SW
J Med Chem; 2018 Jul; 61(14):6002-6017. PubMed ID: 29856609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
